The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
SigVie-003: phase 3 trial in progress of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50%
Reck M, Lu S, O’Byrne K, Barrios C, Tay F, Chafin W, Pavlov D, Negrao M
Poster
Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody-drug conjugate (ADC), plus pembrolizumab: updated results from phase 1 study (SGNB6A-001)
Corral J, Sehgal K, Benítez-Fuentes J-D, Yang M-H, Ye JZ, Kingsley EC, Fontana E, Mark M, Peters S, Toffalorio F, Wang T, Ghorashi S, Lee A, Powell S
Poster
Be6A Lung-01, a phase 3 study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Peters S, Mathias C, Cheng ML, Bridges B, Planchard D, Reck M, Soo R, Zhu Y, Kim E, Yamamoto N
Sigvotatug vedotin | September 13, 2024 | ESMO 2024
C5751002 | NCT06012435